Cargando…

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups

Multiple myeloma (MM), a plasma cell malignancy, remains incurable despite the development of new therapies. Curcumin anti-tumor effects were previously characterized in multiple myeloma, however only few MM cell lines were included in these studies. Since myeloma is a heterogeneous disease it is im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez-Bougie, Patricia, Halliez, Maxime, Maïga, Sophie, Godon, Catherine, Kervoëlen, Charlotte, Pellat-Deceunynck, Catherine, Moreau, Philippe, Amiot, Martine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2014
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622499/ https://www.ncbi.nlm.nih.gov/pubmed/25517601 http://dx.doi.org/10.4161/15384047.2014.986997

Ejemplares similares

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma
por: Kervoëlen, Charlotte, et al.
Publicado: (2015)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma
por: Maïga, S, et al.
Publicado: (2013)

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53(abnormal) myeloma cells independently of the p53 pathway
por: Surget, Sylvanie, et al.
Publicado: (2014)

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways
por: Tessoulin, Benoît, et al.
Publicado: (2018)

The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction
por: Descamps, G, et al.
Publicado: (2012)

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells
por: Chiron, D, et al.
Publicado: (2013)

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
por: Champion, Ophélie, et al.
Publicado: (2023)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes
por: Gomez-Bougie, Patricia, et al.
Publicado: (2013)

Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
por: Gillardin, Pierre-Samuel, et al.
Publicado: (2017)

BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker
por: Tessoulin, Benoît, et al.
Publicado: (2019)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
por: Chiron, David, et al.
Publicado: (2015)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
por: Touzeau, C, et al.
Publicado: (2014)

TLR9 Ligand Induces the Generation of CD20+ Plasmablasts and Plasma Cells from CD27+ Memory B-Cells
por: Geffroy-Luseau, Alexandrine, et al.
Publicado: (2011)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis
por: Bustany, Sophie, et al.
Publicado: (2015)

The Origin of the Plasma-Cell Heterogeneity
por: Pellat-Deceunynck, Catherine, et al.
Publicado: (2015)

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma
por: Hanf, Matthieu, et al.
Publicado: (2016)

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45
por: Descamps, G, et al.
Publicado: (2009)

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma
por: Pouleau, Blandine, et al.
Publicado: (2023)

Generation and characterization of novel anti-DR4 and anti-DR5 antibodies developed by genetic immunization
por: Dubuisson, Agathe, et al.
Publicado: (2019)

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting
por: de Waal, Esther G. M., et al.
Publicado: (2016)

Long-term stabilisation of myeloma with curcumin
por: Zaidi, Abbas, et al.
Publicado: (2017)

Mouse models of human multiple myeloma subgroups
por: Winkler, Wiebke, et al.
Publicado: (2023)

Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
por: Gelbenegger, Georg, et al.
Publicado: (2019)

A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis
por: Gonçalves, Céline S., et al.
Publicado: (2020)

MBRS-43. ELUCIDATING HOW NOVEL EXTRACELLULAR MATRIX SUBTYPES DIFFERENTIALLY IMPACT THE SURVIVAL OF MEDULLOBLASTOMA SUBGROUPS
por: Johnson, James, et al.
Publicado: (2020)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Current Main Topics in Multiple Myeloma
por: Morè, Sonia, et al.
Publicado: (2023)

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition
por: Decombis, Salomé, et al.
Publicado: (2022)

Molecular subtyping for clinically defined breast cancer subgroups
por: Zhao, Xi, et al.
Publicado: (2015)

P01.15. Multiple Myeloma, chemotherapy and curcumin
por: Panutich, E, et al.
Publicado: (2012)

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
por: Bolli, Niccolo, et al.
Publicado: (2018)

Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups
por: Schmitt, Maxime, et al.
Publicado: (2021)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Genotypes and subtypes of hepatitis C virus in Burundi: a particularity in Sub-saharan Africa
por: Ntagirabiri, Rénovat, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6dpv9u31pncbqsvndnif9ocsk5